
Keywords: VL; visceral leishmaniasis; TFL; trifluralin; TFL-A; trifluralin analogues; NanoDDS; nano drug delivery systems; DMPC; dimyristoylphosphatidylcholine; DMPG; dimyristoylphosphoglycerol; FBS; foetal bovine serum; THP-1; human monocytic cell line; I.E.; inco